Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
1(13%)
Results Posted
167%(5 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
2
25%
Ph phase_3
1
13%

Phase Distribution

5

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)

Trials by Status

active_not_recruiting113%
completed338%
withdrawn113%
terminated338%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03282344
completedphase_3

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

NCT03635983
terminatedphase_2

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

NCT04936841
terminatedphase_1

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349
terminatedphase_1

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

NCT03138889
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03282344Phase 2

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active Not Recruiting
NCT03635983Phase 3

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Completed
NCT04936841Phase 2

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Terminated
NCT04730349Phase 1

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Terminated
NCT03138889Phase 1

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Terminated
NCT03772288Phase 1

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Withdrawn
NCT03745807Phase 1

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Completed
NCT02869295Phase 1

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8